THE EPIDEMIOLOGY AND ANTIBIOTICS SENSITIVITY PATTERN OF COAGULASE NEGATIVE STAPHYLOCOCCAL SEPSIS IN NICU
Nilkant Phad* John Hunter Children's Hospital Background: Coagulase negative Staphylococci (CoNS) cause over half of all the late onset neonatal sepsis (LOS). Vancomycin is widely used as first line treatment due to high carriage of the mecA gene in CoNS species, which indicates Methicillin resistance. However, this approach contributes to the emergence of serious Vancomycin resistant bacterial infections and increased health care costs. The aim of this study is to describe the epidemiology and antibiotics sensitivity patterns of CoNS species to aid in safely reducing Vancomycin use in neonatal intensive care units.
Methods: CoNS blood isolates from neonates with LOS admitted to our intensive care unit from January 2012 to December 2014 were examined for the presence of mecA gene, and the susceptibility to Cephazolin, Flucloxacillin, Augmentin, Gentamicin and Vancomycin using a standard disc diffusion method.
Results: Of the 95 recorded LOS episodes, 57% were caused by CoNS and Staph. Capitis was the predominant species. Respiratory deterioration (48%) and temperature instability (42%) were the most common presenting features, and 63% infants required escalation of cardiorespiratory support. No mortality directly attributable to CoNS occurred. 94% of the CoNS isolates were mecA gene positive, and 99% were resistant to Flucoxacillin. Despite mecA positivity, 97% isolates were sensitive to Cephazolin and 95% to Augmentin.
Conclusion: CONs are the most common pathogen in neonatal LOS and are associated with considerable morbidity. Cefazolin should be considered as a potential therapeutic agent for neonatal CoNS sepsis. Further in vitro studies as well as randomized control trials are warranted to asses the safety and efficacy of the alternative antibiotics. Background: Children exposed to gestational diabetes (GDM) in utero are at increased risk of suboptimal neurodevelopment, including attention deficits. Metformin offers an alternative to insulin therapy for GDM but, unlike insulin, crosses the placenta and directly interacts with the fetus raising safety concerns. However, metformin is pro-neurogenic and anti-inflammatory and may provide some fetal neuroprotection.
REDUCED CORTICAL EXCITABILITY
Methods: We used non-invasive brain stimulation techniques to investigate cortical excitability and neuroplasticity in 27 GDMexposed and 11 matched non-GDM-exposed control children, aged 11-13 years. The GDM children were born to participants in the MiG RCT of metformin versus insulin to treat GDM. Saliva was collected immediately prior to brain stimulation for later cortisol analysis.
Results: GDM children had reduced cortical excitability (F (2,32) = 3.39, P = 0.046) compared with controls, and reliable motor potentials could not be evoked in 7 GDM children. Compared with controls, GDM-exposed children had a reduced or absent neuroplastic response (F (1,28) = 6.76, P = 0.015) to brain stimulation, and this was associated with lower cortisol levels than their unexposed peers (P = 0.001), and higher maternal insulin resistance at trial entry (P = 0.023). However, metforminexposed children exhibited more normal neuroplastic responses than insulin-exposed children, despite similar cortisol levels.
Conclusions: Metformin might offer some neuroprotection to GDM-exposed fetuses, but does not prevent HPA axis programming i.e. low basal cortisol. The findings regarding maternal insulin resistance at trial entry suggest that we may not be treating women for GDM early enough in pregnancy to prevent adverse neurological development in the fetus. 
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